Avandia

GlaxoSmithKline Plc (GSK) will reveal detailed results today on an experimental treatment for diabetes thats part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (HGSI), its partner on the drug. Glaxo will present data from two of eight late-stage studies, dubbed Harmony 6 and Harmony 7, of the once-weekly drug albiglutide ahead of the American Diabetes Association...  

GlaxoSmithKline Plc (GSK) may find its next acquisition target where the U.K. drugmaker found the last two: among more than a dozen companies it collaborates with to develop new treatments. Glaxo has stakes in more than 10 publicly-traded companies, including DiaDexus Inc. (DDXS), which develops diagnostics for detecting heart attack and stroke risk, according to data compiled by Bloomberg. The London...  

05/22 DJ GlaxoSmithKline Buys Back 1.8 Million Shares For Treasury 05/22 DJ GlaxoSmithKline Buys Back 1.8 Million Shares For Treasury 05/22 DJ Roche Drugs To Be Key Focus At Upcoming US Cancer Meeting ASCO 05/22 DJ Roche Drugs To Be Key Focus At Upcoming ...  

GlaxoSmithKline Plc (GSK) will reveal detailed results today on an experimental treatment for diabetes that’s part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (HGSI), its partner on the drug. Glaxo will ...  

GlaxoSmithKline PLC (NYSE:GSK) closed Monday's bullish trading session at $44.48. In the past year, the stock has hit a 52-week low of $38.76 and 52-week high of $47.48. GlaxoSmithKline PLC (GSK) stock has been showing support around $44.24 and resistance in the $44.62 range. Technical indicators for the stock are Bearish and S&P gives GlaxoSmithKline PLC (GSK) a weak 2 STARS (out of 5) sell rating. For a hedged play on GlaxoSmithKline PLC...  

(RTTNews) - GlaxoSmithKline plc (GSK: News ,GSK.L: News ) Wednesday amended the conditions of its unsolicited tender offer to acquire Human Genome Sciences (HGSI: News ) for $13.00 per share. The move, the British drug maker said, is in response to a ...  

GlaxoSmithKline plc Wednesday, May 23, tweaked the terms of its hostile $2.59 billion offer for Human Genome Sciences Inc. to address a poison pill mechanism its target put in place last week. Human Genome's plan, implemented as it reiterated its rejection of the offer on May 17, dilutes holdings should a third party attempt to buy up 15% or more of its stock without the board's support. GlaxoSmithKline...  

GlaxoSmithKline PLC said Wednesday that Human Genome Sciences Inc. will need to drop a “poison pill” provision for the takeover of the Rockville biotech to move forward. Human Genome Sciences is GlaxoSmithKline’s partner in developing and marketing the lupus drug Benlysta, which launched last year to lackluster results. The British pharmaceutical in April first sought to scoop up Human Genome Sciences for $2.6 billion, or $13 per share, in a...  

GlaxoSmithKline PLC (GSK) - Director/PDMR Shareholding (Replacement) RNS Number : 7997D GlaxoSmithKline PLC 21 May 2012      This announcement replaces the original announcement released on 11 May 2012 at 15.25 (RNS No: 2041D)   Due to an ...  

Auxilium Pharmaceuticals, Inc. and GlaxoSmithKline entered into an agreement Monday to co-promote Testim, Auxilium's testosterone replacement therapy product used in adult males. Under the terms of the agreement, Auxilium (NASDAQ:AUXL) of Malvern, Pa., granted GSK the exclusive right to co-promote Testim in the United States through Sept.30, 2015. Auxilium and GSK (NYSE:GSK) have agreed on an undisclosed baseline revenue forecast for Testim...  

MADRID (MarketWatch) — London stocks extended the prior day’s gains on Friday, in line with action seen for wider European markets, with heavyweights such as GlaxoSmithKline PLC and utility stocks among the gainers. The FTSE 100 index (FTI ...  

PHILADELPHIA, May 21, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc (LSE: GSK), announced today that they have entered into an agreement for the co-promotion of Testim 1% (testosterone gel), which is indicated for testosterone replacement therapy in adult males for conditions...  

The back and forth maneuvers regarding GlaxoSmithKline’s $2.6 billion bid for Human Genome Sciences continued Wednesday, with GSK amending the conditions of its tender offer to address the HGS board’s adoption of a shareholder rights plan. GlaxoSmithKline said that it has added a condition to its offer requiring HGS to redeem the pill or, alternatively, GSK being satisfied in its reasonable judgment that the pill has been invalidated or is...  

MALVERN, Pa. and PHILADELPHIA, May 21, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc (LSE: GSK), announced today that they have entered into an agreement for the co-promotion of Testim® 1%...  

GlaxoSmithKline said Tuesday that it will acquire the remaining shares that it does not already own in proteomics technologies company Cellzome for $99 million. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK’s R organization. GSK (NYSE: GSK) already has a 19.98 percent equity interest in Cellzome. Cellzome shareholders hope to use the acquisition to create a spin-off...  

Auxilium Pharmaceuticals Inc. (AUXL) raised its full-year outlook as it entered an agreement with the U.S. unit of GlaxoSmithKline PLC (GSK) to co-promote a testosterone replacement therapy. Auxilium and GlaxoSmithKline LLC said they will ...  

GlaxoSmithKline (NYSE: GSK) is increasing its ownership in San Francisco-based Theravance Inc. (Nasdaq: THRX). Following approval Tuesday by Theravance stockholders, GSK’s previously announced acquisition of 10 million shares of Theravance is now complete – meaning GSK owns 25.8 million shares of Theravance common stock. That’s 26.7 percent of the total outstanding capital stock of Theravance. GSK and Theravance long have been collaborators...  

GlaxoSmithKline Plc (GSK)s combination of two experimental melanoma medicines slowed the progress of cancer with few skin complications in an early study, suggesting the combo may not have as many side effects as existing single- drug treatments.Patients taking Glaxos dabrafenib and trametinib together had a lower incidence of rash and skin lesions than previously reported with Roche...  

GlaxoSmithKline is collaborating with Auxilium Pharmaceuticals to promote a testosterone replacement therapy. The agreement, the financial terms of which have not been released, regards Testim, a treatment intended for people with testosterone deficiency. Auxilium has granted GSK an exclusive right to co-promote the drug through September 30, 2015. Auxilium will still be responsible for commercial drug manufacturing and supply regarding...  

GlaxoSmithKline PLC is taking its unsolicited $2.6 bid for Rockville-based Human Genome Sciences Inc. directly to the biotech's shareholders through a tender offer this week, a hostile move that will test GSK's partnership with the smaller firm, the Wall Street Journal reported.  

GlaxoSmithKline plc (GSK) recently announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99M) in cash. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK’s R&D organisation.  

LONDON and SOUTH SAN FRANCISCO, Calif., May 16, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc ("GSK") (LSE:GSK) and Theravance, Inc. ("Theravance") (Nasdaq:THRX) announced today that following approval by Theravance, Inc.'s stockholders at their Annual Meeting held on 15 May 2012, and expiration of applicable waiting periods under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976, GSK's acquisition...  

Now that Human Genome has rejected its $2.6 billion takeover offer, GlaxoSmithKline has decided to put the matter to Human Genome shareholders, Reuters reports. GlaxoSmithKline (NYSE:GSK), which has major operations in the Philadelphia area, is going to launch a tender offer for Human Genome shares this week, Reuters said. GSK announced its offer to buy drug development partner Human Genome Sciences (NASDAQ:HGSI) for $13 a share last month...  

Andrew Cole +1 212 687 8080 (New York) Michael Henson +1 212 687 8080 (New York) Cautionary statement regarding forward-looking statements This communication does not constitute an offer to purchase or a solicitation of an offer to sell any securities.  

The Global Alliance for Vaccines and Immunization announced Thursday that GlaxoSmithKline’s rotavirus vaccine, Rotarix, is being introduced into the newly started national vaccination program in Ghana. The vaccine is aimed at preventing rotavirus-related diarrhea, one of the leading causes worldwide of death in children under five. GSK (NYSE: GSK), which is supplying the vaccine through UNICEF to countries in Africa, has committed to provide...  

LONDON and SOUTH SAN FRANCISCO, Calif., May 16, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc ("GSK") (LSE:GSK) and Theravance, Inc. ("Theravance") (Nasdaq:THRX) announced today that following approval by Theravance, Inc.'s stockholders at their Annual Meeting held on 15 May 2012, and expiration of applicable waiting periods under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976, GSK's acquisition of 10,000,000 shares of Theravance...  

Denmark's Genmab (OMX: GEN) yesterday received a milestone payment of 20 million Danish kroner ($3.4 million from GlaxoSmithKline to Genmab in connection with the recent filing of the New Drug Application to the ...  

MINYANVILLE ORIGINAL GlaxoSmithKline (GSK) launched a hostile bid for Human Genome Sciences (HGSI) Wednesday three weeks after the biotech spurned a $2.6 billion takeover offer. Human Genome also put itself up for sale in April after rejecting Glaxo's $13 per share cash offer. Glaxo which collaborates with Human Genome on drug development made it clear Wednesday it doesn't want to be part of an auction. Glaxo "will not participate in Human...  

Human Genome Sciences Inc, which has rejected a hostile $13-per-share offer from GlaxoSmithKline, has adopted a short-term stockholder rights plan to fend off such unwanted attention. Rockville, Md.-based Human Genome (NASDAQ:HGSI) said in a statement announcing the plan that it had declared a dividend of one share purchase right for each share of the company's common stock held of record at the close of business on May 29. Human Genome said...  

The offer represents a premium of 81 percent to HGS's closing share price of US$7.17 on 18th April, the last trading day before HGS publicly ... a solicitation of an offer to sell HGS common stock.  The solicitation and offer to buy HGS common ...  

Job Title: Bottling Engineer Reference: 140512-5Location: GMS Agbara, Ogun State,NigeriaReporting To (Job Title): Head of EngineeringOrganisation: GlaxoSmithKline – GSK NigeriaJob Purpose/Scope:   To ensure the implementation of maintenance activities (planned  

GlaxoSmithKline in takeover bid for Human Genome LONDON (AP) — GlaxoSmithKline PLC has made an offer to take over U.S. drug maker Human Genome Sciences Inc. which values the company at nearly $2.6 billion. Human Genome Sciences, based in Rockville, Maryland, has a 50-50 profit sharing agreement with GSK on the lupus drug Benlysta, which won regulatory approval in the United States and Europe last year. The two companies are also...  

LONDON -- GlaxoSmithKline (GSK) said Wednesday it is taking its hostile $2.6 billion takeover offer for Human Genome Sciences (HGS) direct to the US biotech's shareholders, by launching a tender offer at $13 a share this week. HGS, a US pioneer of gene-based drug discovery that sells a...  

Human Genome Sciences Inc. formally rejected a recent $2.6 billion hostile takeover bid by GlaxoSmithKline on Thursday. Earlier this month, GlaxoSmithKline (NYSE: GSK) made an unsolicited tender offer to acquire all of HGSI’s outstanding common stock at $13 a share. HGSI officially deemed that offer inadequate Thursday. In a news release, CEO Thomas Watkins said that HGSI (Nasdaq: HGSI) holds “great potential” and the current offer...  

British drug maker GlaxoSmithKline (Nasdaq: GSK) will not be buying smaller rival AstraZeneca (NYSE: AZN). That’s according to GSK CEO Andrew Witty, who told shareholders Thursday that buying a company AstraZeneca’s size would be “distracting,” Reuters reports. GSK has its U.S. headquarters in Research Triangle Park. While it doesn’t have a large presence in the Triangle like GSK, AstraZeneca is well known among local drug makers, including...  

and Sir Chris Kelly, Chair of The King's Fund. The IMPACT Awards, GSK's flagship UK corporate responsibility programme, highlights the crucial role charities play in dealing with some of the most difficult health issues, while promoting innovation and good ...  

GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for Ј61 million (US$99 million) in cash. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK’s R organisation. Cellzome’s proteomics technologies can be used...  

Research-based pharmaceutical and healthcare company GlaxoSmithKline PLC (GSK.LN) said Tuesday it has entered into an agreement to buy the 80.02% of Cellzome AG it doesn't already own for GBP61 million in cash. Cellzome, a privately owned company with laboratories in Cambridge, U.K., and Heidelberg, Germany, will become part of GSK's R organization. Cellzome's proteomics technologies can be used...  

Social network Facebook (NASDAQ:FB ... and remain confident of bringing more transactions to completion in the near future." Broker Numis said: “In light of its track record of earnings accretion from such deals, and the stock's current modest valuation ...  

Job Title: Shift Production ManagerReference: 140512-4Location: GMS Agbara, Ogun State, NigeriaReporting To (Job Title): Manufacturing Operations ManagerOrganisation: GlaxoSmithKline – GSK NigeriaJob Purpose/Scope:   1.   Production Line managers plan, direct and coordinate the operations of their packaging value stream. 2.   He is responsible for e...  

Job Title: Account ManagerReference: 29-11-11:2Location: Lafia / MakurdiReporting To (Job Title): Territory ManagerOrganisation: GlaxoSmithKline – GSK NigeriaJob Purpose/Scope: To manage a Partner or a number of Partner Accounts in a given territory to achieve GSK Revenue and Customer network objectives.Key responsibilities include:•   Achieve P...  

The Food and Drug Administration has approved GlaxoSmithKline's Votrient drug for patients with advanced soft tissue sarcoma who have received prior chemotherapy, the company announced. Paolo Paoletti, the president of oncology at the GlaxoSmithKline (NYSE:GSK), which has major operations in Philadelphia, said Votrient is "one of of the few new medical options to be provided to patients with advanced soft tissue sarcoma over the last thirty...  

GlaxoSmithKline showed how much it values its place in the respiratory market on Monday, investing another $213 million in a company that is developing Relovair, which is widely seen as the successor to GSK’s asthma treatment Advair. GSK (NYSE: GSK) has been working with drug development company Theravance Inc. (Nasdaq: THRX) for a decade now and already owned an 18 percent stake in the San Francisco-based firm. The investment announced...  

GlaxoSmithKline shares drop on Q1 disappointment LONDON (AP) — GlaxoSmithKline PLC reported Wednesday a 13 percent drop in first-quarter net profit compared with a year earlier, when earnings were heavily boosted by the sale of a unit. Profit in the first quarter of 2011 was boosted by the 1.2 billion-pound sale of the company's stake in Quest, a U.S. medical lab operator, and its North American interests in Zovirax cold sore cream.  

Some analysts doubt that GlaxoSmithKline’s recent $2.6 billion hostile bid – at $13 per share – for Human Genome Sciences Inc. is enough. A Reuters survey of analysts has an ideal bid at $15 per share, the average of predictions that varied from $13 to $18.  

Human Genome Sciences Inc. said Thursday morning it has shot down an unsolicited $2.59 billion buyout bid by British pharma giant GlaxoSmithKline plc, its partner in developing and marketing the lupus drug Benlysta. The move by GSK follows months of fresh takeover rumors surrounding the two companies. Human Genome (NASDAQ: HGSI), which has seen its stock pounded down after the sluggish launch of Benlysta last year, in a news release said...  

GlaxoSmithKline has confirmed reports that it wants to buy drug development partner Human Genome Sciences for $2.6 billion. England-based Glaxo (NYSE:GSK), which has major operations in the Philadelphia region, says its offer for Human Genome Sciences (NASDAQ:HGSI) of $13 a share is 81 percent higher than the takeover target’s closing stock price on Wednesday. The New York Times is reporting that Rockville, Md., based Human Genome has...  

Top line results are in from GlaxoSmithKline’s Phase III studies of a type 2 diabetes drug. Albiglutide, an investigational once-weekly glucagon-like peptide-1 agonist, was compared to prepandial insulin and has produced positive results so far. GlaxoSmithKline (NYSE: GSK) announced it had received top line results from seven of the eight “Harmony” Phase III studies, with Harmony 8 to be completed in mid-2012. Five ongoing studies will be...  

Human Genome Sciences (HGSI) wasted no time putting itself up for sale after spurning longtime drug development partner GlaxoSmithKline's (GSK) $2.6 billion unsolicited takeover offer. The $13 per share Glaxo is offering for the biotech company is much too low Human Genome says today. "The offer does not reflect the value inherent" in the company according to a statement. Anticipating a higher price investors bid Human Genome's stock up to $14...  

Job Title: Finance Business AnalystReference: 140512-3Location: Ilupeju, Lagos NigeriaReporting To (Job Title): Finance Planning ManagerOrganisation: GlaxoSmithKline – GSK NigeriaJob Purpose/Scope: To provide management accounting functions and support the Marketing and Sales teams (Business partnering) and other departments in decision making....  

Job Title: Marketing ManagerReference: 050512-1Location: Ilupeju, Lagos NigeriaReporting To (Job Title): Marketing DirectorOrganisation: GlaxoSmithKline – GSK NigeriaJob Purpose/Scope: To co-ordinate and manage all marketing activities for the Nutritionals via great brand communications based on strong insights; consumer led innovations and expe...  

Thanks to a $1.5 million gift from the N.C. GlaxoSmithKline Foundation, N.C. Central University will offer more scholarships and enhance its STEM programs. NCCU has made it a stated goal to graduate more students, particularly women and minorities, with degrees in science, technology, engineering or mathematics – or STEM. The grant will help further that goal.  

Five Prime Therapeutics Inc., a South San Francisco-based biotechnology company, has entered into a drug discovery collaboration with U.K.-based biotechnology giant GlaxoSmithKline — the second collaboration of its kind between the two companies. The collaboration will give GlaxoSmithKline exclusive access to therapeutic drugs developed by Five Prime for refractory asthma and chronic obstructive pulmonary disease. The deal will allow Five...  

Job Title: Internal Audit ManagerReference: 170512-1Location: Ilupeju, Lagos NigeriaReporting To (Job Title): Head Internal AuditOrganisation: GlaxoSmithKline – GSK NigeriaJob Purpose/Scope   1. To partner with other audit and compliance groups to lead the continuous improvement of a reliable risk management framework. 2. For risks that fall wit...  

GlaxoSmithKline CEO Sir Andrew Witty said yesterday that the company believes its rejected $2.6 billion offer for drug development partner Human Genome Sciences (NASDAQ: HGSI) "is in the best interest of shareholders of both companies,” the Philadelphia Inquirer reports. Rockville, Md.-based Human Genome had said GSK (NYSE: GSK), which has major operations in Research Triangle Park, "undervalued the company but that its board would listen to...  

GlaxoSmithKline has made a $2.6 billion hostile bid to take over Rockville, Md.-based drug maker Human Genome Sciences Inc. Human Genome's management rejected a similar bid from GSK, a British drug maker that has its U.S. headquarters in Research Triangle Park, last month.  

British drug company GlaxoSmithKline PLC (NYSE: GSK) reported a 13 percent drop in its first quarter net profit, but did grow its U.S. sales. The pharmaceutical company, which employs about 4,500 at its U.S. headquarters in Research Triangle Park, reported $2.1 billion in profit after tax, down from $2.5 billion last year. Sales in the United States grew 9 percent but declined by 6 percent in Europe. The report comes a week after GSK...  

GlaxoSmithKline said Wednesday that it reduced greenhouse gas emissions from its facilities by 5.3 percent in 2011, and also reduced water use by 6.9 percent. That information was disclosed in the company’s new Corporate Responsibility Report, which added that waste sent to landfills dropped by 25 percent. CEO Andrew Witty says it’s just the beginning. “We are not complacent and we will continue to challenge ourselves in the coming months...  

Human Genome Sciences (HGSI) is doing whatever it can to avoid a hostile takeover by GlaxoSmithKline (GSK). The company says it's talking to what it calls "major" pharmaceutical and biotechnology companies to keep GlaxoSmithKline away. It's a fascinating ...  

GlaxoSmithKline (NYSE: GSK) says its new lung disease drug is still on track for submission this year, despite the mixed clinical trial results released Friday. One-dose Relovair did fare better than GSK’s already existing medicine, twice-daily Advair, in one trial for chronic lung disease, but not both trials. GSK says it is moving forward anyway in filing the drug to treat chronic obstructive pulmonary disease (COPD) in both the United...  

Indias top drug regulatory agency violated laws and colluded with pharmaceutical companies to approve medicines without clinical trials, a parliamentary panel said in a report. The Central Drugs Standard Control Organization which oversees clinical trials and Indias 10,000 drugmakers, approved medicines from companies including Novartis AG (NOVN), GlaxoSmithKline Plc (GSK) and Mumbai-based Cipla...  

MALVERN, Pa. (AP) -- Drug developer Auxilium Pharmaceuticals Inc. improved its outlook for 2012 because of plans to start co-promoting its testosterone gel Testim in the U.S. this summer with British pharmaceutical giant GlaxoSmithKline plc.  

AstraZeneca and GlaxoSmithKline: A chorus of mis-approval One of the more striking aspects about the potential billion-dollar acquisitions recently announced by UK drugs giants AstraZeneca and GlaxoSmithKline, which we discuss in more detail in A bargain missed, was the universally positive welcome they received from analysts and brokers – the so-called ‘sell-side community’. The overwhelming view was that, regardless of the fact they...  

(RTTNews) - GlaxoSmithKline plc (GSK: News ,GSK.L: News ) said it agreed to acquire those shares it does not currently own in Cellzome for $99 million in cash. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg ...  

(AGM Statement) RNS Number : 0254D GlaxoSmithKline PLC 09 May 2012    Following the Annual General Meeting of GlaxoSmithKline plc held on the 3 May 2012, at which all proposed resolutions were duly passed, in accordance with Listing Rule 9.6 ...  

The British drug maker GlaxoSmithKline has changed the terms of its proposed takeover offer for Human Genome Sciences in response to the poison pill adopted by the biotechnology company.  

GlaxoSmithKline Plc (GSK) will this week start a hostile $2.6 billion tender offer for Human Genome Sciences Inc. after the U.S. company, its partner on the Benlysta drug for lupus, dismissed a takeover approach. Glaxo will be offering $13 a ...  

British drugmaker GlaxoSmithKline on Wednesday said it had gone hostile over its $2.6 billion (2.0 billion-euro) takeover bid for US research partner Human Genome Sciences Inc.GlaxoSmithKline, which in April had an informal offer rejected by the US company's board, said it had decided to put its bid directly to the shareholders of HGS. The offer remains $13 per share in cash."GlaxoSmithKline plc today announced that it will ... commence a...  

It was revealed on Thursday that Human Genome Sciences (NASDAQ: HGSI) is in talks with, in its own words "major" pharmaceutical and biotechnology companies in a bid to do whatever it can to avoid a hostile takeover by GlaxoSmithKline (NYSE: GSK).  

Testosterone gel is in a group of drugs often spoken of euphemistically. But the numbers for companies making the product for men are clear and direct, which is why Auxilium Pharmaceuticals Inc., of Malvern, and GlaxoSmithKline announced a deal Monday to try to sell more of Testim, Auxilium’s prescription form of the gel.  

LONDON (Reuters) - An experimental cancer drug developed by Britain's GlaxoSmithKline may add vital months to the lives of melanoma patients whose disease has spread to their brains, according to data from an early-stage trial published on Friday.  

01 May 2012, London UK and Phildelphia USA -- GlaxoSmithKline plc (GSK) and Yale University have established a drug discovery research collaboration to design a potential new class of medicines that degrade disease-causing proteins.The collaboration combines GSK's expertise in medicinal chemistry with Yale's pioneering work on proteolysis targeting chimeric molecules or PROTACs. PROTAC...  

RESEARCH TRIANGLE PARK, N.C., May 16, 2012 /PRNewswire/ -- The North Carolina GlaxoSmithKline Foundation is seeking nominations for local health departments, public health staff, and individuals who have improved the health of North Carolina's children through innovative, collaborative...  

it would be understandable if HGS shareholders feel GSK, after 20 years of collaboration with HGS, is forcing the pace for a reasonIt's like the old days for Simon Dingemans, the former Goldman Sachs deal-maker who quit a couple of years ago to do a proper job as finance director of GlaxoSmithKline (or pursue a long-held ambition, if you prefer his formal explanation). GSK is on the deal warpath again. It's not a mega-merger — just a $2.6bn...  

Triangle Business Journal by Lauren K. Ohnesorge, Staff Writer British drug maker GlaxoSmithKline (Nasdaq: GSK) will not be buying smaller rival AstraZeneca (NYSE: AZN). Thats according to GSK CEO Andrew Witty, who told shareholders Thursday that buying a company AstraZenecas size would be distracting, Reuters reports.GSK has its U.S. headquarters in Research Triangle Park...  

PHILADELPHIA, April 26, 2012 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved Votrient (pazopanib) for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy. The U.S. label contains the following limitations: The efficacy of VOTRIENT...  

848-2998 (toll-free) or by email at HGStender@dfking.com.                                                               This information is provided by RNS The company news service from the London Stock Exchange ...  

A two-drug combination that relieves migraines in adults also works well in adolescents, new research indicates. Although the findings basically support what doctors are already doing, "it is nice to have this officially shown in a study in adolescents," said Dr. Ellen Drexler, associate director of neurology at Maimonides Medical Center in New York City.  

The British drug maker GlaxoSmithKline has changed the terms of its proposed takeover offer for Human Genome Sciences in response to the poison pill adopted by the biotechnology company.  

GSK's offer represents a premium of 81 percent to HGS's closing share price of US$7.17 on 18^th April, the last trading day before HGS publicly ... a solicitation of an offer to sell HGS common stock.  The solicitation and offer to buy HGS ...  

 GlaxoSmithKline Plc (GSK) today announced that it has reached agreement to divest the previously identified non-core OTC brands in its international markets to Aspen Pharmacare Holdings Limited (Aspen) for £164 million in cash.          

BANGALORE (MarketWatch) -- GlaxoSmithKline PLC (NYSE:GSK) said Thursday the company was granted a waiver on conducting clinical trials in India for ambrisentan, its drug to treat pulmonary arterial hypertension, as local rules allow such a ...  

GlaxoSmithKline PLC has made an offer to take over U.S. drug maker Human Genome Sciences Inc. which values the company at nearly $2.6 billion. GlaxoSmithKline, which has profit-sharing agreements with HGS on three drugs but a minimal shareholding, said Wednesday it is offering $13 cash per share for the company. A private offer last month by GSK at the same price was rejected by HGS management ...  

ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has received an unsolicited proposal from GlaxoSmithKline plc (GSK) to acquire HGS for $13.00 per share in cash. The HGS Board of Directors, in consultation with independent financial and legal advisors, has carefully reviewed and considered the GSK offer and has determined that the offer does not reflect the value inherent in HGS. HGS also...  

 Issued: Wednesday, 9 May 2012, London UK GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash GlaxoSmithKline plc (LSE: GSK) today announced that it will not ...  

Anna Stove has been appointed General Manager GlaxoSmithKline (GSK) New Zealand, to succeed Geoff McDonald, effective 1 May 2012. Anna, previously Head of Vaccines GSK New Zealand, said she was grateful to Geoff for his leadership and support during ...  

GlaxoSmithKline's (GSK.L) $2.6 billion offer for Human Genome Sciences (HGSI.O) undervalues the biotech company, according to Taube Hodson Stonex, a leading investor in the U.S. group. "The price that's been offered, although it is a big premium to where the shares were trading, is not high enough," said Mark Evans, a fund manager at Taube, which is the sixth largest investor in Human Genome with a...  

LONDON (Reuters) - GlaxoSmithKline said it would not proceed with its $2.6 billion offer for Human Genome Sciences unless the U.S. biotechnology company dropped a "poison pill" shareholder rights plan imposed to block the deal. Human Genome adopted the stockholder rights plan earlier this month in an attempt to ward off GSK in what is becoming an increasingly acrimonious battle between the companies that together sell new Lupus drug Benlysta...  

LONDON (dpa-AFX) - Der größte britische Pharmakonzern GlaxoSmithKline (GSK) hat im ersten Quartal wegen eines rückläufigen Umsatzes in Europa weniger verdient und umgesetzt als am Markt erwartet wurde. Wie das Unternehmen am Mittwoch in London mitteilte, legte der Umsatz in den ersten drei Monaten zu konstanten...  

COPENHAGEN, Denmark, April 27, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Genmab A/S (Copenhagen:GEN) announced today the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for Arzerra(R) (ofatumumab) for the treatment of chronic lymphocytic leukemia (CLL).  

British drugmaker GlaxoSmithKline said Wednesday it will no longer wait for Human Genome Sciences to consider an acquisition offer and instead appealed directly to the Rockville firm’s shareholders to accept its $13-per-share asking price. Read full article >>  

British drugmaker GlaxoSmithKline said Wednesday it will no longer wait for Human Genome Sciences to consider an acquisition offer and will instead appeal directly to the Rockville firm’s shareholders to accept its $13-per-share asking price. Read full article >>  

Biotech drug developer Human Genome Sciences Inc. has rejected an unsolicited $2.59 billion takeover offer from GlaxoSmithKline PLC, saying it undervalues the company. But the Rockville, Md., company said Thursday that it has decided to explore its strategic options, which could include a potential sale of the company. It invited GlaxoSmithKline to participate in its exploratory [...]  

LONDON and SOUTH SAN FRANCISCO, Calif., April 2, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (Nasdaq:THRX - News) announced today that they have entered into a stock purchase agreement, under which Theravance will issue, and GSK will acquire, 10,000,000 shares of Theravance common stock at a price of $21.2887 per share, for a total investment of $212,887,000.Following...  

LONDON - GlaxoSmithKline PLC has reported a 13 per cent drop in first-quarter net profit compared with a year earlier, when earnings were boosted by the sale of a unit. The pharmaceutical company said Wednesday that profit after tax was 1.325 billion pounds ($2.1 billion), down from 1.525 billion po  

GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board. The decision to go hostile with the $13 a share cash tender offer sets GSK up for a potentially lengthy battle with those Human Genome investors who believe it is not offering enough. "They will do fantastically...  

via forbes.com Nissen is known to investors as one of the cardiologists who first raised alarms about Merck‘s Vioxx, a pain pill that was later withdrawn from the market, then who first raised concerns about GlaxoSmithKline‘s diabetes drug Avandia, which had its use severely restricted. (He deals quickly with the Avandia story on page 213, of Heart411, in the section on what patients should know about meta-analysis, the technique for...  

LONDON (AP) -- GlaxoSmithKline PLC has reported a 13 percent drop in first-quarter net profit compared with a year earlier, when earnings were boosted by the sale of a unit. The pharmaceutical company said Wednesday that profit after tax was 1 ...  

Updated with further information on GlaxoSmithKline's unsolicited bid for Human Genome NEW YORK (TheStreet) -- Human Genome Sciences received an unsolicited buyout proposal of $13 a share in cash, or about $2.6 billion, from GlaxoSmithKline but rejected the offer saying the bid "does not reflect the value inherent" in the company. The Glaxo bid represents an 81% premium to Human Genome's closing price Wednesday of $7.17...  

GSK to go hostile with $2.6 billion Human Genome tender By Ben Hirschler LONDON | Wed May 9, 2012 1:42pm BST (Reuters) - GlaxoSmithKline will take its $2.6 billion (1.6 billion pounds) bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board. The decision to go hostile with the $13 a share cash tender offer sets GSK up for a potentially lengthy battle...  

GlaxoSmithKline Plc (GSK), the U.K.’s largest drugmaker, sold $5 billion of bonds in its first dollar- denominated offering in four years as companies market the most U.S. debt in more than a month. Glaxo issued $1 billion of three-year notes ...  

LONDON (dpa-AFX) - GlaxoSmithKline Plc (GSK, GSK.L) said Tuesday that a Committee of the U.S. Food and Drug Administration has recommended approval of its cancer drug Votrient to treat advanced soft tissue sarcoma. The FDA's Oncologic Drugs Advisory Committee, or ODAC, voted 11 to 2, stating that study results support a...  

GlaxoSmithKline PLC GSK commences tender offer to acquire HGS  

LONDON GlaxoSmithKline PLC (GSK.LN) said Thursday that it will invest more than GBP500 million in manufacturing in the U.K. to boost production of essential ingredients for its pharmaceutical products and vaccines, including the construction of a new factory and up to 1,000 jobs.  

GlaxoSmithKline (NYSE:GSK) is working with a Japanese biotechnology company to see if that companys technology can find potential new cancer treatments. GSKs agreement with Tokyo-based Chiome Bioscience calls for the companies to first conduct a pilot study using Chiomes proprietary technology. Chiomes proprietary platform technology can generate antibodies. Under the agreement, GSK and Chiome...  

CHICAGO, April 17, 2012 /PRNewswire/ -- Seven Summits Research issues critical PriceWatch Alerts for BIDU, PM, GSK, TTM, and JAZZ. To see what our analysts have discovered about these stocks read the Seven Summits Strategic Investments' PriceWatch Alerts at...  

Stiefel Laboratories lost a $1.5 million jury verdict to a former employee who claimed the company bought back his stock at artificially low prices before its acquisition in 2009 by GlaxoSmithKline Plc. (GSK) Timothy Finnerty won the judgment on ...  

GlaxoSmithKline will push ahead with plans to file its experimental once-weekly diabetes drug albiglutide for regulatory approval, following the read-out from a series of clinical trials. Albiglutide belongs to the same class of injectable GLP-1 medicines as Novo Nordisk's Victoza and Byetta, from Amylin Pharmaceuticals and Eli Lilly. Byetta was the first drug of the type. Last November, GSK reported...  

Human Genome Sciences Inc.’s (HGSI) board of directors has advised its stockholders to reject GlaxoSmithKline’s (GSK) tender offer. The offer to acquire all outstanding common shares of Human Genome for $ 13.00 per share was considered ...  

Mar 26, 2012 (GlobeNewswire via COMTEX) -- - GSK enters patent settlement with Genentech regarding ofatumumab - Patents relate to recombinant antibody production - Financial details of settlement not disclosed COPENHAGEN, Denmark, March 26, 2012 (GLOBE NEWSWIRE) -- Genmab A/S (copenhagen:GEN) announced today that GlaxoSmithKline (GSK) has agreed a settlement with Genentech Inc. and City...  

GlaxoSmithKline says it will persist with its bid to take over U.S. company Human Genome Sciences despite the target's new 'poison pill' defense. In a statement issued after the market closed on Thursday, GSK said it believes its $13 per share offer ...  

British drugmaker GlaxoSmithKline on Thursday said it has bid $2.6 billion (1.99 billion-euro) for US research partner Human Genome Sciences Inc.GlaxoSmithKline said it made an offer April 11 at $13 per share in cash, a 81 percent premium to Wednesday's closing share price.  

Human Genome Sciences Inc.'s ( HGSI) board of directors has advised its stockholders to reject GlaxoSmithKline's ( GSK) tender offer. The offer to acquire all outstanding common shares of Human Genome for $ 13.00 per share was considered ...  

GlaxoSmithKline ( GSK) recently announced that it has entered into an agreement to acquire 80.02% shares of a U.K. and Germany-based, privately-owned company, Cellzome, for a cash payment of £61 million (U.S. $99 million). Glaxo already owns 19 ...  

Britain's largest drug company has launched a forthright attack on the NHS's drug rationing body, accusing it of blocking innovation after it failed to approve the first new medicine in a decade to treat the disabling condition lupus. GlaxoSmithKline was unusually critical of the decision by Nice, the National Institute for Health and Clinical Excellence, and also the Scottish Medicines Consortium...  

LONDON and SOUTH SAN FRANCISCO, Calif., March 23, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Theravance, Inc. (Nasdaq:THRX - News) today announced that the registrational programme for Relovair(TM) is now complete. In addition, results from two studies for the once-daily investigational medicine Relovair(TM) (fluticasone furoate "FF"/vilanterol "VI" (FF/VI)) in patients with chronic obstructive...  

Drugmaker GlaxoSmithKline said on Wednesday its $2.6 billion bid for long-time partner Human Genome Sciences was "full and fair" and it was the only obvious owner for the biotechnology firm. After releasing disappointing first-quarter results, Britain's biggest drugmaker insisted its $13 a share offer was generous and Chief Executive Andrew Witty played down the possibility of increasing the price...  

LONDON--(BUSINESS WIRE)--Index Ventures today announced the launch of its first fund solely dedicated to making investments in the life sciences sector. This 150m fund includes investments from several of Indexs largest existing limited partners and two companies, GlaxoSmithKline (GSK) and the venture capital affiliate of the Janssen pharmaceutical companies of Johnson & Johnson (Janssen).  

Two drugs being developed by GlaxoSmithKline Plc - each designed ... Those patients saw median progression-free survival of 10.8 months, Dr Jeffrey Weber of the H. Lee Moffitt Cancer Center in Tampa, Florida, who is also the study's lead author ...  

By Rocco Verducci:I would like to provide balance, as a preamble to my article, by stating that although there was nominal mention of Relovair in the actual transcript of the Q1 Earnings Call itself, the official press release of the Q1 results did contain several lines that addressed the completion of a Relovair registration program and made reference to some top line results (which were not disclosed in the press release) of the direct...  

A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients. (Associated Press)  

The media spotlight is often a double-edged sword. No one knows this better than people who suffer from Avandia severe adverse events and have filed Avandia Lawsuits. And yet, gossip and rumor-mongering aside, the real story here is being overlooked ...  

(Reuters) - Human Genome Sciences Inc said on Thursday it adopted a stockholder rights plan as the biotechnology company defends itself against a $2.6 billion (1.6 billion pounds) hostile takeover bid by drug maker GlaxoSmithKline Plc. Human Genome said ...  

Human Genome Sciences Inc. (HGSI) adopted a shareholder rights plan with a 15% trigger in the wake of GlaxoSmithKline PLC's (GSK, GSK.LN) $2.6 billion hostile takeover bid for the biotech firm and continued to suggest that shareholders reject ...  

via reuters.com (Reuters) - Human Genome Sciences has rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector swept by M activity recently. The pioneer of gene-based drug discovery, which sells a new drug for lupus with GSK, said on Thursday the offer of $13 per share, made in a letter on April 11, did not reflect the value inherent in the company. It has...  

GlaxoSmithKline plc (LSE: GSK) today confirms that it made an offer to the Board of Directors of Human Genome Sciences (HGS, NASDAQ: HGSI) on 11th April proposing to acquire all of the outstanding shares of HGS for US$13.00 per share in cash, representing a 81 percent premium to yesterday’s closing share price.  

via reuters.com May 3 (Reuters) - Britain's biggest drugmaker GlaxoSmithKline has no interest in buying its smaller British rival AstraZeneca, GSK's chief executive said on Thursday. AstraZeneca's future is in flux, following the planned early exit of its CEO David Brennan from June 1, leading some analysts to speculate it might become a takeover target. GSK CEO Andrew Witty, however, told shareholders at the company's AGM that buying a big...  

Human Genome Sciences Inc. filed a plan with regulators Thursday to try to block GlaxoSmithKline P.L.C.’s $2.6 billion takeover offer for the Maryland-based pharmaceutical company. The shareholder-rights plan — a corporate tactic often ...  

ROCKVILLE, Md.--(BUSINESS WIRE)--Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that topline results have been received from seven of the eight Harmony Phase 3 studies investigating the use of albiglutide in type 2 diabetes. Albiglutide was created by HGS using its proprietary albumin-fusion technology, and was licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to...  

A new once-daily AIDS drug from GlaxoSmithKline and its partner Shionogi proved just as good as Merck & Co's twice-daily rival Isentress in a late-stage clinical trial, boosting hopes for the product. Both GSK's new drug dolutegravir and Isentress are so-called integrase inhibitors, a novel class of drugs for fighting HIV/AIDS that block the virus causing the disease from entering cells. Dolutegravir...  

LONDON (Reuters) - Benlysta, a new drug for lupus from GlaxoSmithKline and Human Genome Sciences, has been rejected by Germany's healthcare cost watchdog in a decision that adds to the product's uphill battle in Europe.Related StoriesWorld food prices fall; inflation fear remainsItaly PM seeks online tips in rush to cut spendingPro-Assad gun, knife attack kills 4 - protestersWorld powers urge Iran to give more nuclear accessAviva says 50 pct...  

PARSIPPANY, N.J., March 30, 2012 /PRNewswire/ -- Today, Congressman Frank Pallone (D-NJ) and Congressman Tim Murphy (R-PA) sponsored a Congressional briefing, inviting the heads of nationally recognized health organizations, physicians and policy makers to discuss provisions related to...  

OXFORD, England, March 21, 2012 /PRNewswire/ -- Fintan Walton talks exclusively to Johnson & Johnson (J&J) and GlaxoSmithKline (GSK) about their participation in Index Ventures' latest fund announced today at BIO-Europe Spring in Amsterdam. This €150m fund includes...  

GlaxoSmithKline plc (GSK) and Yale University have established a drug discovery research collaboration to design a potential new class of medicines that degrade disease-causing proteins. The collaboration combines GSK’s expertise in medicinal chemistry ...  

Human Genome Sciences (HGSI) has adopted a stockholder rights plan - known widely as a “poison pill” defense strategy - in an effort to protect itself from a hostile takeover bid by rival drug maker GlaxoSmithKline (GSK). The biotechnology ...  

Tuesday is a big day - and a challenging one - for cancer crews at GlaxoSmithKline and Merck because both companies are scheduled to speak with the U.S. Food and Drug Administration's oncologic drug advisory committee at FDA headquarters in Silver Spring, Md.  

(Reuters) - Human Genome Sciences Inc (HGSI.O) said on Thursday it adopted a stockholder rights plan as the biotechnology company defends itself against a $2.6 billion (1.6 billion pounds) hostile takeover bid by drug maker GlaxoSmithKline Plc ...  

The University of Nottingham is renowned for its scientific excellence, with a broad portfolio of chemistry-based degree courses. GSK has a number of existing relationships with the University including providing support through postgraduate chemistry ...  

Monrovia, CA -- (SBWIRE) -- 04/16/2012 -- Barry A. Morgan, Vice President of Molecular Discovery Research, Site Head in Boston at GlaxoSmithKline to give a Keynote Presentation on “DNA Encoded Libraries: A Disruptive Technology for Lead Discovery” at the 6th Drug Design & Medicinal Chemistry Conference (June 7-8, 2012 in San Diego, CA) Encoded Library Technology (ELT) is a novel approach to lead discovery based upon the creation of large (our...  

LONDON and SOUTH SAN FRANCISCO, Calif., March 23, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Theravance, Inc. (Nasdaq:THRX) today announced that the registrational programme for Relovair(tm) is now complete. In addition, results from two studies for the once-daily investigational medicine Relovair(tm) (fluticasone furoate "FF"/vilanterol "VI" (FF/VI)) in patients with chronic obstructive pulmonary disease (COPD) and results from a...  

GlaxoSmithKline (GSK) plans to invest more than £500 million ($798 million) in the United Kingdom across its manufacturing sites to increase production of key active ingredients for its pharmaceutical products and vaccines.  

Relovair™ is a trademark of the GlaxoSmithKline group of companies. The use of the brand name Relovair™ for FF/VI is approved by regulatory authorities around the world. Under the safe harbor provisions of the U.S. Private Securities Litigation Reform ...  

James Shannon has been named GSK’s Chief Medical Officer (CMO), effective 1 May. James will report to R Chairman Moncef Slaoui and be based in London. He will be accountable for medical governance and patient safety for all of GSK: Pharmaceuticals ...  

GlaxoSmithKline, which has profit-sharing agreements with HGS on three drugs but a minimal shareholding, said Wednesday it is offering $13 cash per share for the company. A private offer last month by GSK at the same price was rejected by HGS ...  

HGSI is currently looking into alternatives to GSK's offer as it feels that it is too low and it has invited GSK to participate in that review. GSK has ... that it is kind of like working with your ex-wife, the day after the divorce hearing.  

MONTREAL - The GlaxoSmithKline Inc. multinational wants to lead the Quebec biotech industry’s revival from the disastrous 2008-2010 recession when risk capital ... Fund program is aimed primarily at the proof-of-concept level and it has come just as ...  

There is no doubt that HGSI has a unique capacity to tinker with molecules and discover entities that are unique and that address bona fide medical (and ... Lupus drug would have a multibillion-dollar label by the end of 2015. As of last quarter, it ...  

Europe's largest drugmaker was swiftly rebuffed last month when it pounced on its long-term partner, which develops antibody drugs. On Wednesday GSK it would not participate in Human Genome's strategic alternatives review process and would instead launch a ...  

May 21 (Reuters) - Auxilium Pharmaceuticals Inc and the U.S. unit of drugmaker GlaxoSmithKline said they will jointly sell Auxilium's testosterone gel, Testim, in the United States. The co-promotion agreement for Testim, which is used to treat ...  

Human Genome Sciences said Thursday that its board of directors again rejected the $2.6 billion takeover offer from GlaxoSmithKline. The two companies have partnerships linking three of HGS's most-promising drugs, which might deter other potential bidders.  

British drug maker GlaxoSmithKline has made a $2.6 billion unsolicited bid to buy Maryland-based Human Genome Sciences. GSK (NYSE: GSK) has offered to purchase Human Genome’s outstanding shares for $13 each, representing an 81 percent premium ...  

we continue to believe it will be difficult for shareholders to ignore the certainty of a cash offer," said Dr Mike Mitchell, analyst at broker Seymour Pierce. Going hostile with a bid runs slightly against the grain for a big pharma company such as Glaxo.  

GlaxoSmithKline PLC (GSK) - Transaction in Own Shares RNS Number : 1068A GlaxoSmithKline PLC 26 March 2012   GlaxoSmithKline plc (the "Company") announces that in accordance with the authority granted by shareholders at the Company's Annual General ...  

GlaxoSmithKline, Britain's biggest drugmaker, confirmed plans today to invest more than £500 million in manufacturing in Britain and said it had selected Ulverston, northern England, as the site for a previously announced biotech plant.  

GlaxoSmithKline PLC said it would take its unsolicited $2.6 billion bid for Human Genome Sciences Inc. directly to the biotech's shareholders through a tender offer this week, a hostile move that will test Glaxo's long-standing partnership with ...  

KARACHI: GlaxoSmithKline (GSK) has reinforced its commitment to Pakistan by announcing it will increase investment in consumer healthcare brands over the next five years. It will do so via the ...  

After failing to reach a buyout deal with Human Genome Sciences (HGSI), GlaxoSmithKline will now make a cash tender offer to the company's shareholders for $13 per share. Considering Human Genome Sciences' top ten shareholders own 78% of the company and ...  

The biotechnology company Human Genome Sciences on Thursday adopted a shareholder rights plan, or poison pill, as it sought to fend off a $2.59 billion takeover offer from the drug maker GlaxoSmithKline. The news comes a week after Glaxo, based ...  

GlaxoSmithKline Plc (GSK) will begin a hostile $2.6 billion tender offer this week for Human Genome Sciences Inc. after the U.S. company, its partner on the Benlysta drug for lupus, rebuffed a takeover approach. Glaxo will offer $13 a share in ...  

LONDON -(MarketWatch)- GlaxoSmithKline PLC (NYSE:GSK) said Wednesday it's taking its hostile $2.6 billion takeover offer for Human Genome Sciences Inc (NASDAQ:HGSI) direct to the U.S. biotech's shareholders, by launching a tender offer at $13 a ...  

GlaxoSmithKline Plc (GSK) will begin a hostile $2.6 billion tender offer this week for Human Genome Sciences Inc. (HGSI) after the U.S. company, its partner on the Benlysta drug for lupus, rebuffed a takeover approach. Glaxo will offer $13 a ...  

GSK remains willing to meet and review its offer with HGS at any time. -GSK shares closed Tuesday at 1407 pence valuing the company at GBP71.83 billion. -By Ian Walker, Dow Jones Newswires; 44-20-7842-9296; ian.walker@dowjones.com  

When the pharmaceutical giant GlaxoSmithKline stepped up to the plate with a $13 a share offer for Human Genome Sciences, the subsequent rejection of the deal came as a bit of a surprise.  

Drugs giant GlaxoSmithKline is to take full control of Cellzome, a company specialising in ... All information is provided free of charge, 'as-is', and you use it at your own risk! The contents of all 'Chat' messages should not be construed as advice ...  

Rockville-based Human Genome Sciences enacted a stockholder rights plan Thursday in an effort to prevent drugmaker GlaxoSmithKline from purchasing the biotech company against the will of its board of directors. The tactic, known as a “poison ...  

has not waited around for bid target Human Genome Sciences to complete a strategic review and has taken its $2.6bn offer direct to the US group's shareholders.Glaxo has offered $13 a share for ...  

Bond sales worldwide are reviving from the slowest month of the year as yields on corporate debt decline to the least since 2010. GlaxoSmithKline Plc (GSK)’s $5 billion offering, its first dollar-denominated sale in more than four years, led ...  

LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN) confirmed Thursday that it made an offer to the board of Human Genome Sciences (HGSI) on April 11 proposing to buy the outstanding shares of Human Genome for $13 each in cash, but said the offer ...  

By The Associated Press LONDON - GlaxoSmithKline PLC has tabled an offer to take over U.S. drug maker Human Genome Sciences Inc. which values the target at nearly $2.6 billion. GlaxoSmithKline, which has ...  

Kolkata, May 14: GlaxoSmithKline Consumer Healthcare (GSKCH), which re-entered the Indian toothpaste market last year launching Sensodyne, hopes to increase its share to double-digits from the current 2 percent, a top company official said Monday.  

In recent quarters, GSK’s revenue was depressed by declining sales of the controversial diabetes drug Avandia, herpes treatment Valtrex and its pandemic flu vaccines. GSK has about 3,800 workers at its North American headquarters in Research ...  

LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN) and Yale University said Tuesday that they have established a drug discovery research collaboration to design a potential new class of medicines that degrade disease-causing proteins. -Under the ...  

March 30 (Reuters) - Moody's disclosures on credit ratings of GlaxoSmithKline Plc (Symbol : GSK) (Caryn Trokie, New York Ratings Unit) (c) Reuters 2012. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing ...  

British drugmaker GlaxoSmithKline said Wednesday it will no longer wait for Human Genome Sciences to consider an acquisition offer and instead appeal directly to the Rockville firm’s shareholders to accept its $13-per-share asking price. Read full article >>  

LONDON - GlaxoSmithKline PLC reported Wednesday a 13 percent drop in first-quarter net profit compared with a year earlier, when earnings were heavily boosted by the sale of a unit. GlaxoSmithKline shares were down 2.4 percent at 1,422 pence as ...  

On Wednesday, GlaxoSmithKline, the large British drug maker, announced it would offer investors $13 a share, rebuffing an invitation by Human Genome Science to participate in the strategic review process. The bid represents a 81 percent premium ...  

LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN), the drug company, said Monday that it and biopharmaceutical company Theravance have entered into a partnership for GlaxoSmithKline will acquire, 10,000,000 shares of Theravance common stock at a ...  

The target company has started a strategic review that it hopes will encourage rival bids. But the likelihood of a rival offer is limited, given that three of HGS' major drugs are joint ventures with ... New Jersey A new family attraction featuring 31 ...  

The multinational drug maker's comments come in response to an Indian parliamentary panel report that said ... 10:27a DJ OncoMed Pharmaceuticals Unveils Plans for $115 Million IPO 10:27a DJ OncoMed Pharmaceuticals Unveils Plans for $115 Million IPO 05/10 ...  

LONDON (dpa-AFX) - Stiefel, a GlaxoSmithKline plc (GSK, GSK.L) company, said Friday that the US Food and Drug Administration has approved the New Drug Application for Fabior, or tazarot...  

LONDON (Reuters) - GlaxoSmithKline launched its promised $2.6 billion tender for shares in long-time partner Human Genome Sciences on Thursday, setting out an initial timetable of just under a month to win control. The offer to buy all the outstanding ...  

(RTTNews) - British drug major GlaxoSmithKline Plc (GSK: News ) on Monday said Shionogi-ViiV Healthcare LLC's SPRING-2 Phase III study with HIV drug dolutegravir met its primary objective. The study demonstrated non-inferiority of dolutegravir to ...  

ROCKVILLE, Md. (AP) — Biotech drugmaker Human Genome Sciences Inc. has rejected an unsolicited $2.59 billion takeover bid by GlaxoSmithKline PLC, the British pharmaceutical giant that spent nearly two decades helping the smaller company bring its first ...  

were prescribed the drug in order to lower their blood sugar levels. Tens of thousands of suits have been settled by GlaxoSmithKline to resolve claims that its drug Avandia increased the risk of heart attack in Type 2 diabetes patients. Plaintiff attorneys ...  

ROCKVILLE, Md. — Biotech drugmaker Human Genome Sciences Inc. has rejected an unsolicited $2.59 billion takeover bid by GlaxoSmithKline PLC, the British pharmaceutical giant that spent nearly two decades helping the smaller company bring its first drug to market.  

In February 2011, GSK announced its intention to divest its non-core Consumer Healthcare OTC products to realise value for shareholders and simplify the business by enabling it to focus on priority brands and markets. Agreements were reached in December ...  

GlaxoSmithKline said it will take its $2.6 billion bid for Human Genome Sciences directly to shareholders, a hostile move that will test Glaxo's long-standing partnership with the smaller firm.  

NEW YORK (Reuters) - GlaxoSmithKline will need to sweeten its $13 per share bid for Human Genome Sciences to about $15 per share to win over its top investors and get a deal done, according to a Reuters survey of analysts on Wednesday. The number ...  

It also said it won’t participate in HGS’ “strategic alternatives” review process. The current HGS share price of US$14.62 suggests American investors were expecting a higher offer. In London, the mood was a little more realistic. “We noted last ...  

(RTTNews) - GlaxoSmithKline plc (GSK: News ,GSK.L: News ) said it would not participate in Human Genome Sciences (HGSI: News ) strategic alternatives review process and would instead commence a tender offer this week to acquire HGS' outstanding shares for ...  

However, none of the company’s early experiments panned out. The company originally tested Benlysta as a treatment for rheumatoid arthritis after its discovery in 1996. Glaxo exercised an option from a longstanding agreement between the companies that ...  

Biotech drugmaker Human Genome Sciences Inc. has rejected an unsolicited $2.59 billion takeover bid by GlaxoSmithKline PLC, the British pharmaceutical giant that spent nearly two decades helping the smaller company bring its first drug to market.  

BANGALORE – GlaxoSmithKline Pharmaceuticals Ltd. (500660.BY) said Monday net profit for the first quarter through March soared to INR1.23 billion from INR4.6 million a year earlier, when it was hit by an exceptional charge related to a drug ...  

TEL AVIV (MarketWatch) -- GlaxoSmithKline PLC, (NYSE:GSK) (LSS:UK:GSK) the U.K. health-care major, said on Thursday that it would invest more than £500 million ($794 million) to build its first U.K. plant in 40 years and to add to two current ...  

GlaxoSmithKline Plc (GSK) won U.S. clearance to expand marketing of its 2-year-old kidney-cancer pill Votrient for rare malignancies known as soft-tissue sarcomas. The Food and Drug Administration approved the drug for patients with tumors in ...  

GlaxoSmithKline and Yale University have established a new drug discovery research collaboration to design a potential new class of medicines that kill disease-causing proteins. Under the agreement, a joint research team will work to show that Yale's ...  

May 02--Yale and pharmaceutical giant GlaxoSmithKline have partnered to develop molecules that fight disease-causing proteins, and may lead to the development of new drugs. The partnership is the latest in a series of similar deals as pharmaceutical ...  

GlaxoSmithKline Plc (GSK), the U.K.’s largest drugmaker, reported first-quarter profit and sales that missed analyst estimates as revenue declined in Europe. Earnings excluding some items was 27.3 pence a share, London-based Glaxo said in a ...  

On Wednesday, GlaxoSmithKline, the large British drug maker, announced it would offer investors $13 a share, rebuffing an invitation by Human Genome Sciences to participate in the strategic review process. The bid is 81 percent above the company ...  

Human Genome Sciences Inc has rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline Plc, marking a new takeover battle in a drugs sector that has been swept by M recently.